← Return to Rapid Reccurance and Short Doubling Time after RARP
DiscussionRapid Reccurance and Short Doubling Time after RARP
Prostate Cancer | Last Active: Dec 20, 2024 | Replies (26)Comment receiving replies
Replies to "Doc, thank you for that account of journey. I'm very happy for your outcome! I note..."
Doc, based on your response I did some followup. What you described as treatment for your mHSPC was the use of hormone therapy (Lupron), an androgen receptor pathway inhibitor (darolutamide), and chemotherapy (docetaxel). This treatment was approved as of 2023 and is refered to "triplet" therapy and would now be considered the SOC.
What is a bit of a conumdrum are the guys with Grade 5 disease with short time to BCR, short PSADT's, and other predictors of matastasis, yet the PSMA PET scan shows no MET's. The fact that no MET's are identified could be false negatives from the scan (PSMA negative PC) or it could be the MET's are too small to detect, yet all stakeholders know there is micromatastisis, if not outright matastisis going on. The SOC here is going to be salvage radiation with possibly an androgen receptor pathway inhibitor, and NO chemotherapy.
This is where it seems appropriate to assume this individual is not just having BCR, but in fact has mHSPC. In this case I suspect the patient is going to have to work hard to add the third leg of chemotherapy to the protocol as it is not the SOC.
My mistake; I omitted my pelvic radiation. After my triple therapy, while still on Lupron, I received 37 radiation treatments to my pelvis, including boost to my prostate bed and the location of the one positive node. My MO at Hopkins said to have maximal beneficial effect the radiation needed to be started 8-12 post chemo.